EFR3A

Across TCGA pan-cancer cohorts, EFR3A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of EFR3A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EFR3A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types EFR3A is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where EFR3A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EFR3A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	−0.315	<.001	10	view →
COAD	Male	III,IV	−0.454	<.001	9	view →
HNSC	All	All	+0.125	.003	6	view →
LUAD	Male	III,IV	−0.246	.001	3	view →
OV	All	All	−0.330	.020	2	view →
PDAC	All	IV	+0.583	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

EFR3A–CCRCC

Open the CCRCC breakdown →